2C-B produced MDMA-like and psilocybin-like effects in a head-to-head comparison
Twenty-four healthy volunteers received all three drugs in a crossover trial. At 30 mg, 2C-B matched MDMA's intensity and produced psilocybin-like states, without psilocybin's anxiety.
2C-B is a synthetic phenethylamine that's circulated recreationally for decades but has drawn newer research interest for potentially sharing therapeutic properties with MDMA and psilocybin, both under active investigation for PTSD and depression. A study published this week in Neuropsychopharmacology directly compared 2C-B against both drugs in the same volunteers under controlled conditions, aiming to establish where it sits pharmacologically between the two [s1].
The design
Twenty-four healthy participants (12 women, 12 men) completed a double-blind, randomized, placebo-controlled, crossover trial, receiving 2C-B at three doses (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin on separate occasions [s1]. Researchers measured acute subjective effects, autonomic (cardiovascular) effects, adverse effects, emotional and cognitive empathy, plasma oxytocin and neurophysin I concentrations, and pharmacokinetics for up to 9 hours after dosing [s1].
What it found
2C-B produced dose-dependent subjective effects. At the highest tested dose, 30 mg, 2C-B's overall "any drug effects" intensity was comparable to 125 mg MDMA, though lower than 25 mg psilocybin's [s1]. Only psilocybin induced "bad drug effects" and "anxiety" relative to placebo — neither 2C-B nor MDMA did, at the doses tested [s1]. The 30 mg dose of 2C-B induced psychedelic-type alterations of consciousness and increased emotional empathy similarly to MDMA [s1]. Average subjective effects lasted 4.9 hours for 30 mg 2C-B, close to MDMA's 4.8 hours and shorter than psilocybin's 6.1 hours [s1].
The three drugs diverged on physiology. MDMA produced the strongest cardiovascular stimulation, followed by psilocybin and then 2C-B [s1]. Only MDMA increased plasma oxytocin and neurophysin I — hormones tied to social bonding and the "empathogenic" effects MDMA is known for [s1]. That's a specific and clinically relevant divergence: even though 30 mg 2C-B matched MDMA's overall subjective intensity and its boost to emotional empathy, it did so without triggering the oxytocin release that's thought to underlie some of MDMA's distinctive prosocial effects — suggesting 2C-B and MDMA may reach similar subjective territory through different biological routes. 2C-B showed dose-proportional pharmacokinetics with a plasma elimination half-life of about 1.3 hours [s1].
Why researchers are interested in 2C-B specifically
MDMA and psilocybin are each furthest along in clinical development for PTSD and depression respectively, but each carries its own drawbacks — MDMA's cardiovascular stimulation and psilocybin's potential for a distressing "bad trip," both documented again in this trial [s1]. A compound that could reproduce useful therapeutic properties of either — entactogenic (empathy-enhancing, MDMA-like) or psychedelic (perception-altering, psilocybin-like) effects — without carrying the same specific downsides, would be pharmacologically useful to characterize, which is the stated rationale behind this comparison [s1]. This trial doesn't test 2C-B's therapeutic efficacy for any condition; it establishes descriptive pharmacology, aimed, per the authors, at assisting future dose-finding for 2C-B research [s1].
What this does and doesn't establish
This is a phase 1-style pharmacology study in 24 healthy volunteers — not a patient population, and not a trial testing 2C-B for any psychiatric condition. The findings describe acute effects in a controlled, single-dose, supervised research setting; they say nothing about how 2C-B behaves at the doses and settings in which it's actually used recreationally, where dosing is unsupervised and product purity is unverified — a gap that matters given 2C-B has circulated outside clinical or research contexts for years. Twenty-four participants is a small trial by clinical standards, adequate for detailed pharmacological characterization but not for detecting rare adverse effects.
What to watch
Whether 2C-B advances into trials testing therapeutic efficacy for a specific psychiatric condition, building on this pharmacological groundwork. 2C-B is a Schedule I controlled substance in the United States and is not approved for any medical use; this article describes a controlled pharmacology study and is not medical advice.
Sources
Sources
More on
Psychedelics triggered mania in up to 30% of naturalistic bipolar cases, rarely in trials
A review pooling 23 studies found risk concentrated among people with bipolar I disorder, family history, or unsupervised use. About 4% later transitioned to bipolar disorder.
Largest single-site psilocybin brain-imaging study finds context shapes the response
In 62 adults scanned under psilocybin during rest, meditation, music, and film, brain networks reorganized differently by setting — and more reorganization tracked with more positive experiences.
One psilocybin dose eased chronic suicidal ideation for 12 weeks, in 20 patients
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
The largest psilocybin depression trial yet missed its primary endpoint
EPISODE randomized 144 people with treatment-resistant depression across four arms. High-dose psilocybin missed its main outcome, even as secondary measures showed symptom benefit.